SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Öhrfelt Annika 1973 ) "

Sökning: WFRF:(Öhrfelt Annika 1973 )

  • Resultat 1-10 av 32
  • [1]234Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Sjödin, Simon, et al. (författare)
  • Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
  • 2017
  • Ingår i: Proteomics - Clinical Applications. - John Wiley and Sons Inc.. - 1862-8346. ; 11:11-12
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: Dysfunctional proteostasis, with decreased protein degradation and an accumulation of ubiquitin into aggregated protein inclusions, is a feature of neurodegenerative diseases. Identifying new potential biomarkers in cerebrospinal fluid (CSF) reflecting this process could contribute important information on pathophysiology. Experimental design: A developed method combining SPE and PRM-MS is employed to monitor the concentration of ubiquitin in CSF from subjects with Alzheimer's disease (AD), Parkinson's disease (PD), and progressive supranuclear palsy (PSP). Four independent cross-sectional studies are conducted, studies 1–4, including controls (n = 86) and participants with AD (n = 60), PD (n = 15), and PSP (n = 11). Results: The method shows a repeatability and intermediate precision not exceeding 6.1 and 7.9%, respectively. The determined LOD is 0.1 nm and the LOQ range between 0.625 and 80 nm. The CSF ubiquitin concentration is 1.2–1.5-fold higher in AD patients compared with controls in the three independent AD-control studies (Study 1, p < 0.001; Study 2, p < 0.001; and Study 3, p = 0.003). In the fourth study, there is no difference in PD or PSP, compared to controls. Conclusion and clinical relevance: CSF ubiquitin may reflect dysfunctional proteostasis in AD. The described method can be used for further exploration of ubiquitin as a potential biomarker in neurodegenerative diseases.
2.
  • Olsson, Bob, 1969-, et al. (författare)
  • CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
  • 2016
  • Ingår i: The Lancet. Neurology. - 1474-4465. ; 15:7
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease biomarkers are important for early diagnosis in routine clinical practice and research. Three core CSF biomarkers for the diagnosis of Alzheimer's disease (Aβ42, T-tau, and P-tau) have been assessed in numerous studies, and several other Alzheimer's disease markers are emerging in the literature. However, there have been no comprehensive meta-analyses of their diagnostic performance. We systematically reviewed the literature for 15 biomarkers in both CSF and blood to assess which of these were most altered in Alzheimer's disease.
  •  
3.
  • Bhattacharjee, Payel, 1984-, et al. (författare)
  • Mass Spectrometric Analysis of Lewy Body-Enriched alpha-Synuclein in Parkinson's Disease
  • 2019
  • Ingår i: Journal of Proteome Research. - 1535-3893. ; 18:5, s. 2109-2120
  • Tidskriftsartikel (refereegranskat)abstract
    • Parkinson's disease (PD) is characterized by intraneuronal inclusions of aggregated alpha-synuclein protein (so-called Lewy bodies) in distinct brain regions. Multiple posttranslational modifications may affect the structure and function of alpha-synuclein. Mass spectrometry-based analysis may be useful for the characterization and quantitation of alpha-synuclein forms, but has proven challenging, mainly due to the insolubility of Lewy bodies in aqueous buffer. In the present study, we developed a novel method by combining differential solubilization with immunoprecipitation and targeted proteomics using liquid chromatography and tandem mass spectrometry. Brain tissue homogenization and sample preparation were modified to facilitate analysis of soluble, detergent-soluble, and detergent-insoluble protein fractions (Lewy body-enriched). The method was used to compare alpha-synuclein forms from cingulate cortex (affected) and occipital cortex (unaffected) in two study sets of PD patients and controls. We identified similar to 20 modified alpha-synuclein variants, including species with N-terminal acetylation and C-terminal truncations at amino acids 103 and 119. The levels of alpha-synuclein forms Ac-alpha-syn(1-6), alpha-syn(13-21), alpha-syn(35-43), alpha-syn(46-58), alpha-syn(61-80), and alpha-syn(81-96) except alpha-syn(103-119) were significantly increased in PD cingulate region compared to controls in the Lewy body-enriched alpha-synuclein fraction. In the soluble fraction, only Ac-alpha-syn(1-6) was significantly increased in PD compared to controls. None of the detected alpha-synuclein variants were Lewy body-specific, but acetylated forms should be examined further as potential biomarkers for abnormal alpha-synuclein accumulation.
  •  
4.
  • Brinkmalm, Ann, et al. (författare)
  • Detection of α-Synuclein in Biological Samples Using Mass Spectrometry
  • 2019
  • Ingår i: Methods in molecular biology (Clifton, N.J.). - Springer. - 1940-6029. ; s. 209-220
  • Bokkapitel (refereegranskat)abstract
    • Here we describe a method using mass spectrometry to characterize and quantify immuno-enriched α-synuclein forms from biochemically fractionated brain tissue.
  •  
5.
  • Brinkmalm, Ann, et al. (författare)
  • SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease
  • 2014
  • Ingår i: Molecular Neurodegeneration. - BioMed Central (BMC). - 1750-1326. ; 9
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Synaptic degeneration is an early pathogenic event in Alzheimer's disease, associated with cognitive impairment and disease progression. Cerebrospinal fluid biomarkers reflecting synaptic integrity would be highly valuable tools to monitor synaptic degeneration directly in patients. We previously showed that synaptic proteins such as synaptotagmin and synaptosomal-associated protein 25 (SNAP-25) could be detected in pooled samples of cerebrospinal fluid, however these assays were not sensitive enough for individual samples. Results: We report a new strategy to study synaptic pathology by using affinity purification and mass spectrometry to measure the levels of the presynaptic protein SNAP-25 in cerebrospinal fluid. By applying this novel affinity mass spectrometry strategy on three separate cohorts of patients, the value of SNAP-25 as a cerebrospinal fluid biomarker for synaptic integrity in Alzheimer's disease was assessed for the first time. We found significantly higher levels of cerebrospinal fluid SNAP-25 fragments in Alzheimer's disease, even in the very early stages, in three separate cohorts. Cerebrospinal fluid SNAP-25 differentiated Alzheimer's disease from controls with area under the curve of 0.901 (P < 0.0001). Conclusions: We developed a sensitive method to analyze SNAP-25 levels in individual CSF samples that to our knowledge was not possible previously. Our results support the notion that synaptic biomarkers may be important tools for early diagnosis, assessment of disease progression, and to monitor drug effects in treatment trials.
6.
  • Brinkmalm, Gunnar, et al. (författare)
  • An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid.
  • 2012
  • Ingår i: Journal of mass spectrometry : JMS. - 1096-9888. ; 47:5, s. 591-603
  • Tidskriftsartikel (refereegranskat)abstract
    • Amyloid precursor protein (APP) is the precursor protein to amyloid β (Aβ), the main constituent of senile plaques in Alzheimer's disease (AD). Endogenous Aβ peptides reflect the APP processing, and greater knowledge of different APP degradation pathways is important to understand the mechanism underlying AD pathology. When one analyzes longer Aβ peptides by low-energy collision-induced dissociation tandem mass spectrometry (MS/MS), mainly long b-fragments are observed, limiting the possibility to determine variations such as amino acid variants or post-translational modifications (PTMs) within the N-terminal half of the peptide. However, by using electron capture dissociation (ECD), we obtained a more comprehensive sequence coverage for several APP/Aβ peptide species, thus enabling a deeper characterization of possible variants and PTMs. Abnormal APP/Aβ processing has also been described in the lysosomal storage disease Niemann-Pick type C and the major large animal used for studying this disease is cat. By ECD MS/MS, a substitution of Asp7 → Glu in cat Aβ was identified. Further, sialylated core 1 like O-glycans at Tyr10, recently discovered in human Aβ (a previously unknown glycosylation type), were identified also in cat cerebrospinal fluid (CSF). It is therefore likely that this unusual type of glycosylation is common for (at least) species belonging to the magnorder Boreoeutheria. We here describe a detailed characterization of endogenous APP/Aβ peptide species in CSF by using an online top-down MS-based method.
  •  
7.
  • Brinkmalm, Gunnar, et al. (författare)
  • Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.
  • 2013
  • Ingår i: Brain research. - 1872-6240. ; 1513, s. 117-26
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: Cerebral accumulation of amyloid beta (A beta) is a pathological hallmark of Alzheimer's disease (AD). Proteolytic processing of amyloid precursor protein (APP) by alpha- or beta-secretase results in two soluble metabolites, sAPP alpha and sAPP beta, respectively. However, previous data have shown that both alpha- and beta-secretase have multiple cleavage sites. The aim of this study was to characterize the C-termini of sAPP alpha and sAPP beta in cerebrospinal fluid (CSF) by mass spectrometry (MS) and to evaluate whether different combinations of these fragments better separate between AD patients and controls by comparing two different sAPP immunoassays. Methods: Using immunoprecipitation and high resolution MS, the APP species present in CSF were investigated. CSF levels of sAPP alpha and sAPP beta from patients with AD (n=43) and from non-demented controls (n=44) were measured using AlphaLISA and MSD immunoassays that employ different antibodies for C-terminal recognition of sAPP alpha. Results: Four different C-terminal forms of sAPP were identified, sAPP beta-M671, sAPP beta-Y681, sAPP alpha-Q686, and 5APP alpha-K687 (APP770 numbering). Neither immunoassay for the sAPP species could separate the two patient groups. The correlation (R-2) between the two immunoassays was 0.41 for sAPP alpha and 0.45 for sAPP beta. Conclusion: Using high resolution MS, we show here for the first time that sAPP alpha in CSF ends at Q686 and K687. The findings also support the conclusion from several previous studies that sAPP alpha and sAPP beta levels are unaltered in AD. (C) 2013 Elsevier B.V. All rights reserved.
  •  
8.
  • Brinkmalm-Westman, Ann, 1966-, et al. (författare)
  • Explorative and targeted neuroproteomics in Alzheimer's disease.
  • 2015
  • Ingår i: Biochimica et biophysica acta. - 0006-3002. ; 1854:7
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease (AD) is a progressive brain amyloidosis that injures brain regions involved in memory consolidation and other higher brain functions. Neuropathologically, the disease is characterized by accumulation of a 42 amino acid peptide called amyloid β (Aβ42) in extracellular senile plaques, intraneuronal inclusions of hyperphosphorylated tau protein in neurofibrillary tangles, and neuronal and axonal degeneration and loss. Biomarker assays capturing these pathologies have been developed for use on cerebrospinal fluid samples but there are additional molecular pathways that most likely contribute to the neurodegeneration and full clinical expression of AD. One way of learning more about AD pathogenesis is to identify novel biomarkers for these pathways and examine them in longitudinal studies of patients in different stages of the disease. Here, we discuss targeted proteomic approaches to study AD and AD-related pathologies in closer detail and explorative approaches to discover novel pathways that may contribute to the disease. This article is part of a Special Issue entitled: Neuroproteomics: Applications in neuroscience and neurology.
  •  
9.
  • Brinkmalm-Westman, Ann, 1966-, et al. (författare)
  • Targeting synaptic pathology with a novel affinity mass spectrometry approach.
  • 2014
  • Ingår i: Molecular & cellular proteomics : MCP. - 1535-9484. ; 13:10, s. 2584-92
  • Tidskriftsartikel (refereegranskat)abstract
    • We report a novel strategy for studying synaptic pathology by concurrently measuring levels of four SNARE complex proteins from individual brain tissue samples. This method combines affinity purification and mass spectrometry and can be applied directly for studies of SNARE complex proteins in multiple species or modified to target other key elements in neuronal function. We use the technique to demonstrate altered levels of presynaptic proteins in Alzheimer disease patients and prion-infected mice.
  •  
10.
  • Bäckström, David C, et al. (författare)
  • Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
  • 2015
  • Ingår i: JAMA NEUROLOGY. - 2168-6149 .- 2168-6157. ; 72:10, s. 1175-1182
  • Tidskriftsartikel (refereegranskat)abstract
    • Alterations in cerebrospinal fluid (CSF) have been found in Parkinson disease (PD) and in PD dementia (PDD), but the prognostic importance of such changes is not well known. In vivo biomarkers for disease processes in PD are important for future development of disease-modifying therapies.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 32
  • [1]234Nästa
Åtkomst
fritt online (4)
Typ av publikation
tidskriftsartikel (30)
bokkapitel (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (32)
övrigt vetenskapligt (1)
Författare/redaktör
Blennow, Kaj, 1958-, (23)
Zetterberg, Henrik, ... (21)
Öhrfelt, Annika, 197 ... (19)
Brinkmalm-Westman, A ... (9)
Brinkmalm, Gunnar, (9)
Hansson, Oskar, (7)
visa fler...
Brinkmalm, Ann, (7)
Zetterberg, Henrik, (6)
Wallin, Anders, 1950 ... (6)
Ohrfelt, Annika (6)
Minthon, Lennart, (5)
Blennow, Kaj (5)
Portelius, Erik, 197 ... (4)
Andreasson, Ulf, 196 ... (4)
Vanmechelen, Eugeen (4)
Bjerke, Maria, 1977- ... (4)
Londos, Elisabet, (3)
Blennow, K (3)
Vanmechelen, E (3)
Nägga, Katarina, (3)
Hall, Sara (3)
Zetterberg, H (2)
Wallin, A (2)
Rolstad, Sindre, 197 ... (2)
Olsson, Bob, 1969-, (2)
Forsgren, Lars, (2)
Linder, Jan, (2)
Tysnes, Ole Bjørn, (2)
Svensson, Johan, 196 ... (2)
Alves, Guido (2)
Lange, Johannes (2)
Andreasen, Niels, (2)
Andreasen, N, (2)
Nordlund, Arto, 1962 ... (2)
Bhattacharjee, Payel ... (2)
Edman, Åke, (2)
Jonsson, Michael, 19 ... (2)
Eckerström, Carl, (2)
Andreasson, Ulf, (2)
Gobom, Johan, (2)
Honer, William G. (2)
Sjödin, Simon, (2)
Persson, Rita, 1951- ... (2)
Nutu, Magdalena (2)
Olsson, Erik, 1960-, (2)
Trupp, Miles (2)
Eckerström, Marie, 1 ... (2)
Göthlin, Mattias, 19 ... (2)
Førland, Marthe Guri ... (2)
Surova, Yulia, (2)
visa färre...
Lärosäte
Göteborgs universitet (32)
Lunds universitet (7)
Karolinska Institutet (3)
Språk
Engelska (32)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (32)
Naturvetenskap (1)
Teknik (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy